Since its introduction in January, has sent shockwaves across the pharmaceutical sector. Although the Act does not propose a blanket prohibition, its definition of prohibiting federal funding for “biotechnology equipment or service” from a “biotechnology company of concern”, has raised concerns about the Act’s impact on collaborations with Chinese companies in particular. Specifically, the prohibition of the purchase of equipment or contracting services from Chinese companies like WuXi AppTec and WuXi Biologics, using US federal funds, has come under the spotlight.
Many small and large pharmaceutical companies depend on federal grants, through the US and the , to finance their clinical programmes. The gold standard of business intelligence. The Act also leaves room to include other to-be-identified entities that are subject to the control of a “foreign adversary”, namely China, North Korea, Iran, Cuba, and Russia.
In an exclusive interview with , Anshul Mangal, President of Project Farma, a consulting firm specialising in manufacturing and technical operations for complex biologics and novel therapies, talks about the impact of BIOSECURE Act on pharmaceutical companies and outlines the steps the companies can take to mitigate its impact. . Pharma companies prefer Chinese CDMOs like WuXi as they are cost-effective and efficient.
That is a big driver for reliance on these CDMOs. A by the US trade association BIO found that 79% of the 124 US companies surveyed had .
